NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma

作者:Corradi Massimo*; Chrystyn Henry; Cosio Borja G; Pirozynski Michal; Loukides Stelios; Louis Renaud; Spinola Monica; Usmani Omar S
来源:Expert Opinion on Drug Delivery, 2014, 11(9): 1497-1506.
DOI:10.1517/17425247.2014.928282

摘要

Introduction: Airway inflammation and remodelling in asthma occur in the large airways and also in the small airways. The small airways are those %26lt; 2 mm in diameter and are significant sites of chronic asthmatic inflammation. It is important, therefore, to target the small as well as the large airways in any strategy for effective treatment of this disease. %26lt;br%26gt;Areas covered: The present review deals with the recently developed fixed dose drug combination of beclometasone dipropionate/formoterol fumarate that emits extrafine particles when delivered from an innovative dry powder inhaler (DPI), NEXThaler (R). The aim is to present the technical and clinical aspects of aerosolized drug delivery to the lungs. %26lt;br%26gt;Expert opinion: The data show that the NEXThaler DPI is an efficient device for the management of persistent asthma. The evaluation of the inhalation profiles through the NEXThaler DPI demonstrates that device activation and consistent dose delivery occurs at patient achievable inhalation flow rates, and supports the broad utility of the NEXThaler DPI in patients with asthma. Overall, all the effectiveness, efficiency and satisfaction outcomes demonstrate the NEXThaler DPI is easy to use.

  • 出版日期2014-9